SEC Form 4 · accession 0001179110-17-013135
Aralez Pharmaceuticals Inc. · ARLZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Patrick Tursi
Officer — Chief Medical Officer
Period of report
Oct 2, 2017
Accepted (ET)
Oct 4, 2017 · 8:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001660719
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares, without par valueF2 | Oct 2, 2017 | S | 9,960 | $2.5018 | D | 257,350 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This represents shares sold by the issuer on behalf of the reporting person pursuant to an instruction made in accordance with Rule 10b5-1 for payment of withholding tax liability incurred upon the vesting of 29,000 restricted stock units, which vested on October 1, 2017. 7,284 of such restricted stock units were previously granted on October 1, 2015 and 21,716 of such restricted stock units were previously granted on February 12, 2016.
- F2This transaction was executed in multiple trades at prices ranging from $2.50 to $2.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.